A Phase 2 interventional study of Ezogabine and Placebos in Depressive Disorder and Anhedonia, sponsored by James Murrough. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-10-23.
Sponsored by James Murrough · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 319 studies in Depressive Disorder with a site in United States — 38 open to participants now, 44 under way, 2 of them phase 3. Depressive Disorder · United States.
Among the 319 studies in Depressive Disorder with a site in United States, this one is the 182nd largest by enrollment of the 275 interventional ones that give a count, is one of 17 that started in 2017, is one of 49 in phase 2, and was the 174th registered.
857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.
Browse Depressive Disorder studies →38 of the 319 studies in Depressive Disorder with a site in United States are open now. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, Brazil and 12 more countries
Ages 18–75
Ksana Health · Sites in United States
Ages 13–24
University of California, San Diego · Sites in United States
Ages 18–65
Mayo Clinic · Sites in United States
Ages 12–17
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
319 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 61 · Phase 3 41 · Phase 4 34
First in 1988; this study’s year is marked. 17 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 87 across 691 interventional studies indexed under Depressive Disorder.
Median enrollment 85 across the 275 interventional studies, 149 across the 40 observational. Of the 260 that completed or were terminated, 98 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
79 of 319 have an industry lead sponsor. The 10 most frequent:
James Murrough is the lead sponsor of 9 studies on the registry; none are open to participants now.
James Murrough has 1 study filed under Depressive Disorder — fewer than ten, so there is no comparison to draw.
16 of the studies in Depressive Disorder with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07841483Slingshot AIAI Mental Health Tool vs. Psychoeducation Control | 2026-12 |
| NCT06508450New York UniversityA Mental Health Services Engagement Program for Racial and Ethnic Minority Young Adults | 2026-12 |
| NCT05282277University of North Carolina, Chapel HillExamining the Effects of Estradiol on Neural and Molecular Response to Reward | 2026-12-31 |
| NCT05920252Ksana HealthA Digitally Assisted Risk Reduction Platform for Youth at High Risk for Suicide | 2026-12-31 |
| NCT05011864University of Texas at AustinIntegrated Tele-Behavioral Activation and Fall Prevention for Low-income Homebound Seniors With Depression | 2026-12-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 319 studies in Depressive Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener ezogabine (Potiga, GlaxoSmithKline; FDA-approved for the treatment of seizure disorders).
Depressive disorders are among the most disabling medical conditions worldwide and currently available treatments fall short of addressing this large public health burden. Dysfunction within the brain reward system is emerging as a core feature of depressive disorders, in particular related to deficits in motivation, interest, and response to pleasure (e.g., anhedonia: markedly diminished response to pleasure). Evidences from a series of preclinical studies from our group highlighted the KCNQ subtype of neuronal potassium (K+) channel as a novel target for the treatment of depressive disorders and our human pilot study showed a reduction in anhedonia and related symptoms, and an increased brain response to reward (as measured by functional magnetic resonance imaging [fMRI]) following treatment with ezogabine. Building on this data, the current project will assess reward circuit activity following treatment with ezogabine in depressed patients with a current depressive disorder (Major depressive disorder [MDD], persistent depressive disorder, other specified depressive disorder) and anhedonia (defined by a score ≥ 20 on the Snaith-Hamilton Pleasure Scale [SHAPS]), using fMRI to investigate the cortico-striatal circuit to reward.
This study represents the first part of the R61/R33 National Institutes of Health (NIH) founded project. A clear increase in reward circuit activation in at least one ezogabine treatment group compared to placebo, given acceptable tolerability, will constitute a "go" and the project will move to the next phase (R33), where we aim to examine the relationship between treatment, reward circuit activity, and behavioral and clinical outcomes in a larger, confirmatory efficacy trial of ezogabine for depression with anhedonia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History of non-response to electroconvulsive therapy in the current depressive episode
Exceptions:
Medically appropriate episodic use (up to 3 days) of narcotic analgesics for acute medical indications is allowed (Discussion with PI required)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive treatment with ezogabine up to 900mg/day.
Drug: Ezogabine
Participants will receive treatment with a matching placebo pill.
Drug: Placebos
daily for 5 weeks
Also known as: Potiga
placebo pill daily for 5 weeks
Change in Ventral Striatum (VS) Activation
change in activation during reward anticipation within the bilateral VS from baseline (Study Visit 0) to the primary outcome visit (Study Visit 5) as measured by functional MRI during the incentive flanker task (IFT). The IFT, like the Monetary Incentive Delay task, permits discrete modeling of brain activity during anticipation of an incentive. Functional scans were preprocessed and denoised for motion and physiological noise using multi-echo independent component analysis (ME-ICA). Task-based modeling was conducted using AFNI and FSL software. The primary outcome for reward anticipation was the contrast of reward cue compared to neutral cue (reward\>neutral cue). The primary imaging outcome was analyzed using a linear mixed model with a single random intercept term treating time as discrete or continuous as appropriate.
Time frame: baseline and 5 weeks
Change in Snaith-Hamilton Pleasure Scale (SHAPS)
The SHAPS is a well-validated 14-item self-report questionnaire commonly used to assess anhedonia. Each item on the SHAPS is worded so that higher scores indicate greater pleasure capacity. A total score can be derived by summing the responses to each item. Items answered with "strongly agree" are coded as "1", while a "strongly disagree" response was assigned a score of "4." Total scores on the SHAPS can range from 14 to 56, with higher scores corresponding to higher levels of anhedonia.
Time frame: baseline and 5 weeks
Clinical Global Impression - Improvement (CGI-I)
A widely administered clinician rated global measure of the degree of improvement from the initial assessment in subject overall illness severity. 7 point scale rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.
Time frame: baseline and 5 weeks
Clinical Global Impression - Severity (CGI-S)
Clinician rated global measure of subject overall illness severity. a 7-point scale rated as 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
Time frame: baseline and 5 weeks
Anticipatory and Consummatory Interpersonal Pleasure Scale (ACIPS)
A measure specifically designed to assess hedonic capacity for social and interpersonal pleasure.The ACIPS is a 17-item self-report measure scored on a likert scale, ranging from 1 (very false for me) to 6 (very true for me). Full scale from 17-102, higher score indicates higher hedonic capacity
Time frame: baseline and 5 weeks
Montgomery-Asberg Depression Rating Scale (MADRS)
A 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each items is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression).
Time frame: baseline and 5 weeks
World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)
A 12-item generic assessment instrument that measures the level of functioning. Each item is scored from 0 to 4 and the items are summed to provide a total score. The score therefore ranges from 0 to 48, with higher scores indicating greater disability.
Time frame: baseline and 5 weeks
Temporal Experience of Pleasure Scale (TEPS)
The TEPS is composed of 18-items rated on a likert-type scale ranging from 1 (Very True for me) to 6 (Very False for me), and yields two subscales. Ten items make up the TEPS-Anticipatory Pleasure (TEPS-ANT) scale with a range from 10 (not motivated) to 60 (highly motivated). The other eight TEPS items make up the TEPS-Consummatory Pleasure (TEPS-CON) scale; range from 8 (not responsive) to 48 (highly responsive). Total scores range is 18-108. Lower scores indicate greater levels of anhedonia.
Time frame: baseline and 5 weeks
Specific Loss of Interest and Pleasure Scale (SLIPS)
The SLIPS is a recently developed and validated measure of anhedonia that is tailored to detect recent changes in anhedonia. A 23-item measure, each item range from 0-3. Full scale from 0 to 69, higher score indicates more recent changes.
Time frame: baseline 5 weeks
Participants recruited from Sept 2017 through August 2019
| Milestone | Ezogabine | Placebo |
|---|---|---|
| Started | 21 | 24 |
| Completed | 20 | 21 |
| Not completed | 1 | 3 |
| Withdrew: Discontinued intervention | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
change in activation during reward anticipation within the bilateral VS from baseline (Study Visit 0) to the primary outcome visit (Study Visit 5) as measured by functional MRI during the incentive flanker task (IFT). The IFT, like the Monetary Incentive Delay task, permits discrete modeling of brain activity during anticipation of an incentive. Functional scans were preprocessed and denoised for motion and physiological noise using multi-echo independent component analysis (ME-ICA). Task-based modeling was conducted using AFNI and FSL software. The primary outcome for reward anticipation was the contrast of reward cue compared to neutral cue (reward\>neutral cue). The primary imaging outcome was analyzed using a linear mixed model with a single random intercept term treating time as discrete or continuous as appropriate.
| Bold Oxygen-level Dependent (BOLD) Signa | Ezogabine | Placebo |
|---|---|---|
| baseline | -0.26 ± 0.69 | 0.95 ± 0.79 |
| 5 weeks | 0.176 ± 0.81 | 0.015 ± 0.68 |
The SHAPS is a well-validated 14-item self-report questionnaire commonly used to assess anhedonia. Each item on the SHAPS is worded so that higher scores indicate greater pleasure capacity. A total score can be derived by summing the responses to each item. Items answered with "strongly agree" are coded as "1", while a "strongly disagree" response was assigned a score of "4." Total scores on the SHAPS can range from 14 to 56, with higher scores corresponding to higher levels of anhedonia.
| score on a scale | Ezogabine | Placebo |
|---|---|---|
| Baseline | 38.7 ± 8.1 | 33.7 ± 6 |
| 5 weeks | 27.5 ± 8.5 | 30 ± 10.9 |
A widely administered clinician rated global measure of the degree of improvement from the initial assessment in subject overall illness severity. 7 point scale rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.
| score on a scale | Ezogabine | Placebo |
|---|---|---|
| baseline | 4 ± 0.2 | 4 ± 0.4 |
| 5 weeks | 2.1 ± 1 | 2.8 ± 1.3 |
Clinician rated global measure of subject overall illness severity. a 7-point scale rated as 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
| score on a scale | Ezogabine | Placebo |
|---|---|---|
| baseline | 4.4 ± 0.5 | 4.6 ± 0.6 |
| 5 weeks | 2.6 ± 1.2 | 3.3 ± 1.2 |
A measure specifically designed to assess hedonic capacity for social and interpersonal pleasure.The ACIPS is a 17-item self-report measure scored on a likert scale, ranging from 1 (very false for me) to 6 (very true for me). Full scale from 17-102, higher score indicates higher hedonic capacity
| score on a scale | Ezogabine | Placebo |
|---|---|---|
| baseline | 46.1 ± 15.1 | 53.7 ± 15 |
| 5 weeks | 65.1 ± 22.8 | 59 ± 23.5 |
A 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each items is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression).
| score on a scale | Ezogabine | Placebo |
|---|---|---|
| baseline | 28.3 ± 6.1 | 26.8 ± 5.1 |
| 5 weeks | 12.7 ± 8.7 | 18.5 ± 10.1 |
A 12-item generic assessment instrument that measures the level of functioning. Each item is scored from 0 to 4 and the items are summed to provide a total score. The score therefore ranges from 0 to 48, with higher scores indicating greater disability.
| score on a scale | Ezogabine | Placebo |
|---|---|---|
| baseline | 15.5 ± 7.5 | 16.5 ± 9.4 |
| 5 weeks | 10.2 ± 9.5 | 11.6 ± 9.8 |
The TEPS is composed of 18-items rated on a likert-type scale ranging from 1 (Very True for me) to 6 (Very False for me), and yields two subscales. Ten items make up the TEPS-Anticipatory Pleasure (TEPS-ANT) scale with a range from 10 (not motivated) to 60 (highly motivated). The other eight TEPS items make up the TEPS-Consummatory Pleasure (TEPS-CON) scale; range from 8 (not responsive) to 48 (highly responsive). Total scores range is 18-108. Lower scores indicate greater levels of anhedonia.
| score on a scale | Ezogabine | Placebo |
|---|---|---|
| TEPS-ANT baseline | 26.3 ± 8.3 | 28.6 ± 8.7 |
| TEPS-ANT 5 weeks | 37.3 ± 10.5 | 32.4 ± 11.5 |
| TEPS-CON baseline | 24.8 ± 8.1 | 25.6 ± 7.6 |
| TEPS-CON 5 weeks | 32.2 ± 6 | 29.9 ± 10.5 |
The SLIPS is a recently developed and validated measure of anhedonia that is tailored to detect recent changes in anhedonia. A 23-item measure, each item range from 0-3. Full scale from 0 to 69, higher score indicates more recent changes.
| score on a scale | Ezogabine | Placebo |
|---|---|---|
| baseline | 32.3 ± 9.8 | 28.8 ± 10.4 |
| 5 weeks | 16.3 ± 16.7 | 21.5 ± 16.8 |
Collected over 8 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ezogabine | 0/21 (0%) | 0/21 (0%) | 21/21 (100%) |
| Placebo | 0/24 (0%) | 0/24 (0%) | 19/24 (79.2%) |
| Event | Ezogabine | Placebo |
|---|---|---|
| DizzinessNervous system disorders | 21/21 | 5/24 |
| OtherGeneral disorders | 9/21 | 8/24 |
| HeadacheNervous system disorders | 5/21 | 7/24 |
| DiarrheaGastrointestinal disorders | 5/21 | 1/24 |
| NauseaGastrointestinal disorders | 3/21 | 5/24 |
| Confusional statePsychiatric disorders | 4/21 | 0/24 |
| Disturbance in attentionNervous system disorders | 3/21 | 0/24 |
| Vision blurredEye disorders | 3/21 | 1/24 |
| Abdominal PainGastrointestinal disorders | 2/21 | 3/24 |
| SomnolenceNervous system disorders | 2/21 | 3/24 |
| Age, Continuous(years) | Ezogabine | Placebo | Total |
|---|---|---|---|
| Mean | 44.4 ± 13.6 | 38.9 ± 14.3 | 41.5 ± 14.1 |
| Sex: Female, Male(Participants) | Ezogabine | Placebo | Total |
|---|---|---|---|
| Female | 10 | 12 | 22 |
| Male | 11 | 12 | 23 |
| Race/Ethnicity, Customized(Participants) | Ezogabine | Placebo | Total |
|---|---|---|---|
| White/Caucasian | 12 | 12 | 24 |
| Black/African American | 5 | 7 | 12 |
| Hispanic/Latino | 6 | 9 | 15 |
| Employment at least Part-Time(Participants) | Ezogabine | Placebo | Total |
|---|---|---|---|
| Count of participants | 9 | 14 | 23 |
| Educational Attainment - ast least some college(Participants) | Ezogabine | Placebo | Total |
|---|---|---|---|
| Count of participants | 15 | 21 | 36 |
| Relationship Status - Single, Never Married(Participants) | Ezogabine | Placebo | Total |
|---|---|---|---|
| Count of participants | 8 | 13 | 21 |
| Primary Diagnosis(Participants) | Ezogabine | Placebo | Total |
|---|---|---|---|
| Major Depressive Disorder | 21 | 23 | 44 |
| Persistent Depressive Disorder | 0 | 1 | 1 |
| Current Major Depressive Episode(Participants) | Ezogabine | Placebo | Total |
|---|---|---|---|
| Count of participants | 21 | 22 | 43 |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this study may be submitted to the National Database for Clinical Research Related to Mental Illness (NDCT). NDCT isa data repository run by the National Institute of Mental Health (NIMH) that allows researchers studying mental illness to collect and share deidentified information with each other. During and after the study, the researchers will send deidentified information about health and behavior and in some cases, genetic information, to NDCT. Other researchers nationwide can then file an application with the NIMH to obtain access to deidentified study data for research purposes.
Ran from Sep 2017 to primary completion in Aug 2019, 23 months.
Results were first posted in Oct 2020, 1 year 1 month after primary completion.
Of 43 phase 2 interventional studies under Depressive Disorder, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 23 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ezogabine
James Murrough